Analysts Set Pfizer Inc. (NYSE:PFE) Price Target at $28.50

Pfizer Inc. (NYSE:PFE) has earned an average recommendation of “Hold” from the twenty-one brokerages that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $28.50.

A number of research firms have issued reports on PFE. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday. Wolfe Research restated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research report on Tuesday, June 9th. Finally, CICC Research assumed coverage on Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s roughly 6.9% dividend yield is more than six times the S&P 500 average, making the shares attractive to income-oriented investors despite their weak five-year performance. Pfizer’s Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield?
• Positive Sentiment: Pfizer is among five major pharmaceutical companies expected to report second-quarter results this week, and a strong start to the broader pharma earnings season has raised hopes that the company could beat forecasts. Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
• Positive Sentiment: Analyst price targets tracked over the past six months have a median of $27.50, above Pfizer’s recent trading level, suggesting some potential upside if earnings and management’s outlook reassure investors. Pfizer Stock Opinions on Pipeline Developments and Market Valuation
• Neutral Sentiment: Wall Street expects lower second-quarter earnings when Pfizer reports, placing greater importance on revenue trends, cost controls, pipeline progress and full-year guidance. Pfizer Reports Q2 2026 Earnings Tomorrow
• Neutral Sentiment: The broader market opened with a favorable tone as falling oil prices supported equities, though this is a general market tailwind rather than a Pfizer-specific catalyst. Falling Oil Boosts Wall Street Pre-Bell
• Negative Sentiment: Pre-earnings coverage highlights pressure from legacy products and the need for newer growth bets to offset declining COVID-related sales, reinforcing concerns about Pfizer’s medium-term growth profile. Pfizer, Merck Q2 Preview
• Negative Sentiment: Social-media discussion continues to raise questions about vaccine safety perceptions, Pfizer’s pipeline execution and limited buyer interest; these concerns may weigh on sentiment ahead of the earnings release, although they are not verified company announcements. Pfizer Stock Opinions on Pipeline Developments and Market Valuation

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after acquiring an additional 7,031,162 shares in the last quarter. State Street Corp grew its holdings in shares of Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after purchasing an additional 1,184,728 shares in the last quarter. Morgan Stanley increased its position in shares of Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Finally, Norges Bank purchased a new stake in Pfizer in the fourth quarter valued at approximately $1,830,986,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.2%

NYSE:PFE opened at $25.05 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a market cap of $142.77 billion, a P/E ratio of 19.12 and a beta of 0.34. The firm’s fifty day moving average is $25.03 and its 200-day moving average is $26.16. Pfizer has a 52 week low of $23.40 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the company earned $0.92 EPS. Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. Equities analysts expect that Pfizer will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s payout ratio is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.